Abstract Library

#3039 Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)

Introduction: In many cases, the cause of death in patients with carcinoid syndrome (CS) is carcinoid heart disease (CHD) which is most often diagnosed in patients with SI-NEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ćwikła J

Authors: Konsek-Komorowska S, Pęczkowska M, Kolasińska-Ćwikła A, Cichocki A, Roszkowska-Purska K,

Keywords: Neuroendocrine Neoplasms of the Small Intestine, SI-NENs, carcinoid syndrome, carcinoid heart disease, Overall Survival,

#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)

Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cwikla J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Lanreotide AG systemic therapy,

#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ćwikla J

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,

Keywords: NENs, PRRT, Hindgut, CUP,

#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)

Introduction: SSA are the first line therapy in well differentiated pNET

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kolasińska-Ćwikla A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Bednarczuk T, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Octreotide LAR therapy,

#1934 Neuroendocrine Carcinomas Pancreatic Origin, Polish Experience

Introduction: Pancreatic neuroendocrine carcinomas (NEC) including poorly differentiated (NECG3), mixed type (MANEC) and NETG3 are rare of pancreatic neuroendocrine neoplasms.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk A, Cichocki A, Roszkowska-Purska K, Maciejkiewicz K,

Keywords: NEC of the pancreas, OS, Ki67, CS,